Image_8_A Synergistic Combination of DHA, Luteolin, and Urolithin A Against Alzheimer’s Disease.JPEG
Alzheimer’s disease (AD) is a devastating neurodegenerative disorder and the most common form of dementia worldwide. The classical AD brain is characterized by extracellular deposition of amyloid-β (Aβ) protein aggregates as senile plaques and intracellular neurofibrillary tangles (NFTs), composed of hyper-phosphorylated forms of the microtubule-associated protein Tau. There has been limited success in clinical trials for some proposed therapies for AD, so attention has been drawn toward using alternative approaches, including prevention strategies. As a result, nutraceuticals have become attractive compounds for their potential neuroprotective capabilities. The objective of the present study was to derive a synergistic nutraceutical combination in vitro that may act as a potential preventative therapy for AD. The compounds of interest were docosahexaenoic acid (DHA), luteolin (LUT), and urolithin A (UA). The cell viability and cytotoxicity assays MTS and LDH were used to evaluate the compounds individually and in two-compound combinations, for their ability to inhibit Aβ1–42-induced toxicity in human neuroblastoma BE(2)-M17 cells. The LDH-derived% protection values were used in the program CompuSyn v.1.0 to calculate the combination index (CI) of the two-compound combinations. The software-predicted potentially synergistic (CI < 1) two-compound combinations were validated using CellTiter Glo assay. Finally, a three-compound combination was predicted (D5L5U5) and shown to be the most effective at inhibiting Aβ1–42-induced toxicity. The synergistic combination, D5L5U5 warrants further research for its mechanism of action; however, it can serve as a basis to develop an advanced functional food for the prevention or co-treatment of AD.
History
References
- https://doi.org//10.1186/1471-2202-14-49
- https://doi.org//10.1038/s42255-019-0073-4
- https://doi.org//10.3233/JAD-150136
- https://doi.org//10.1159/000484066
- https://doi.org//10.1007/s00394-003-0396-4
- https://doi.org//10.4068/cmj.2014.50.2.45
- https://doi.org//10.1080/10408398.2012.752342
- https://doi.org//10.1111/j.1368-5031.2005.00769.x
- https://doi.org//10.2174/138945011793591626
- https://doi.org//10.1021/acs.jnatprod.6b00643
- https://doi.org//10.1155/2013/270418
- https://doi.org//10.1093/jn/133.6.1913
- https://doi.org//10.1186/s12974-019-1450-3
- https://doi.org//10.1074/jbc.M110.182329
- https://doi.org//10.1016/j.nbd.2006.08.006
- https://doi.org//10.1111/jcmm.12714
- https://doi.org//10.1371/journal.pone.0034402
- https://doi.org//10.18632/oncotarget.1969
- https://doi.org//10.1523/JNEUROSCI.4225-04.2005
- https://doi.org//10.1016/j.freeradbiomed.2020.02.024
- https://doi.org//10.1080/15384047.2017.1394542
- https://doi.org//10.1371/journal.pone.0160870
- https://doi.org//10.1080/13543784.2017.1323868
- https://doi.org//10.3390/md16010003
- https://doi.org//10.1152/ajpheart.1999.276.1.H149
- https://doi.org//10.1038/nm.4132
- https://doi.org//10.1093/jn/136.10.2481
- https://doi.org//10.1016/j.nbd.2018.11.026
- https://doi.org//10.1021/jm3009458
- https://doi.org//10.1016/j.jalz.2015.06.1895
- https://doi.org//10.1016/j.phytochem.2003.07.001
- https://doi.org//10.1016/j.jacbts.2020.03.010
- https://doi.org//10.1517/17425247.2011.618183
- https://doi.org//10.3390/molecules21040452
- https://doi.org//10.5551/jat.23697
- https://doi.org//10.3233/JAD-142517
- https://doi.org//10.1007/s12011-012-9411-z
CC BY 4.0